Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RAJYALAKSHMI LUTHRA and RUSSELL BROADDUS.
RAJYALAKSHMI LUTHRA
Connection Strength
3.079
RUSSELL BROADDUS
  1. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019 03; 32(3):405-414.
    View in: PubMed
    Score: 0.164
  2. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol. 2018 07; 31(7):1036-1045.
    View in: PubMed
    Score: 0.157
  3. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271.
    View in: PubMed
    Score: 0.153
  4. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
    View in: PubMed
    Score: 0.149
  5. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.
    View in: PubMed
    Score: 0.146
  6. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.
    View in: PubMed
    Score: 0.145
  7. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.
    View in: PubMed
    Score: 0.145
  8. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers. Int J Gynecol Pathol. 2016 Jan; 35(1):8-15.
    View in: PubMed
    Score: 0.135
  9. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol. 2014 Aug; 134(2):319-25.
    View in: PubMed
    Score: 0.121
  10. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.120
  11. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
    View in: PubMed
    Score: 0.118
  12. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.118
  13. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013 Oct; 26(10):1401-12.
    View in: PubMed
    Score: 0.112
  14. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med. 2012 May; 136(5):510-6.
    View in: PubMed
    Score: 0.105
  15. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012 May; 25(5):699-708.
    View in: PubMed
    Score: 0.103
  16. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila). 2012 Feb; 5(2):320-7.
    View in: PubMed
    Score: 0.102
  17. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008 Dec 20; 26(36):5965-71.
    View in: PubMed
    Score: 0.082
  18. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 06; 27(52):6667-78.
    View in: PubMed
    Score: 0.081
  19. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20; 25(33):5158-64.
    View in: PubMed
    Score: 0.076
  20. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006 Jan 01; 106(1):87-94.
    View in: PubMed
    Score: 0.068
  21. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol. 2004 Aug; 17(8):981-9.
    View in: PubMed
    Score: 0.061
  22. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80.
    View in: PubMed
    Score: 0.059
  23. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.051
  24. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.047
  25. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet. 2018 10; 226-227:17-22.
    View in: PubMed
    Score: 0.040
  26. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.
    View in: PubMed
    Score: 0.040
  27. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072.
    View in: PubMed
    Score: 0.039
  28. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
    View in: PubMed
    Score: 0.035
  29. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
    View in: PubMed
    Score: 0.035
  30. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol. 2016 Feb; 145(2):222-37.
    View in: PubMed
    Score: 0.034
  31. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.033
  32. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.
    View in: PubMed
    Score: 0.033
  33. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.033
  34. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.032
  35. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.032
  36. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014 Oct-Dec; 207(10-12):495-502.
    View in: PubMed
    Score: 0.031
  37. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
  38. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.